Multi-Gram Synthesis of a Hyaluronic Acid Subunit and Synthesis of Fully Protected Oligomers
aqueous phase was extracted with THF (3ꢂ10 mL). The
water and subsequently with catalytic amount of
Pd(OH)2 on charcoal in the presence of hydrogen to
give 36.
combined organic phases were collected, dried over sodium
sulfate and evaporated to yield compound 35. The crude
product was purified by preparative HPLC (yield: 26 mg,
15%). MS-MALDI for C79H88N2O27 [M+Na]: m/z=1519.8
Methyl 2-O-benzoyl-b-d-glucopyranosyluronate)-(1!3)-
(4-O-acetyl-2-deoxy-2-acetamido-b-d-glucopyranosyl)-(1!
4)-(methyl 2-O-benzoyl-b-d-glucopyranosyluronate)-(1!3)-
4-O-acetyl-2-deoxy-2-acetamido-b-d-glucopyranoside (36):
Allyl (methyl 2-O-benzoyl-3-O-benzyl-b-d-glucopyranosyl-
Conclusions
Herein we describe the synthesis of the modular dis-
accharide subunit of hyaluronic acid on a multi-gram
scale, as well as the synthesis of the corresponding,
fully protected, tetra-, hexa- and octamers on a scale
of several 100 mg. The first deprotection strategy was
demonstrated on the tetrasaccharide and gave promis-
ing results to achieve the full deprotection.
AHCTUNGTRENNUNG
benzyl-b-d-glucopyranosyluronate)-(1!3)-4-O-acetyl-6-O-
benzyl-2-deoxy-2-acetamido-b-d-gluco-pyranoside
(35)
(0.015 g, 0.01 mmol) was dissolved in AcOH (1 mL). Water
(0.2 mL) was added, followed by addition of NaOAc
(0.0125 g, 0.15 mmol) and PdCl2 (0.0035 g, 0.02 mmol), and
the mixture was stirred for 12 h at room temperature. The
reaction mixture was diluted with EtOAc and water, and
aqueous NaHCO3 was added until neutralization. The aque-
ous layer was extracted with EtOAc (3ꢂ10 mL), dried over
Na2SO4, filtered and concentrated under vacuum to yield
the product 36. The crude product was used without further
purification in subsequent reaction. MS-MALDI: for
C76H84N2O27 [M+Na]: m/z=1479.8.
Experimental Section
General Remarks
All reactions were performed in oven-dried glassware under
an argon atmosphere. Solvents and chemicals used were pur-
chased from commercial suppliers. Solvents were dried
under standard conditions. All materials were used without
further purification. Thin-layer chromatography (TLC) was
carried out on silica gel plates (silicagel 60, F254, Merck)
with detection by UV and visualized by Seebach solution.
Purification was performed with preparative chromatogra-
phy using normal-phase silica gel (silica gel 60, 230–400
mesh, Merck). IR spectra were recorded on a Bruker IFS88.
Crude methyl 2-O-benzoyl-3-O-benzyl-b-d-glucopyrano-
syluronate)-(1!3)-(4-O-acetyl-6-O-benzyl-2-deoxy-2-acet-
amido-b-d-glucopyranosyl)-(1!4)-(methyl 2-O-benzoyl-3-
O-benzyl-b-d-glucopyranosyluronate)-(1!3)-4-O-acetyl-6-
O-benzyl-2-deoxy-2-acetamido-b-d-glucopyranoside
(36)
was subsequently dissolved in MeOH (1 mL) and catalytic
amounts of Pd(OH)2 were added. The reaction mixture was
stirred at room temperature under a hydrogen atmosphere
(hydrogen balloon) overnight. After completion, the catalyst
was filtered and washed with MeOH. The filtrate was
evaporated to give the product 36. The crude product was
purified by preparative HPLC (4 mg, 37% over 2 steps).
MS-MALDI measurement for C48H60N2O27 [M+Na]: m/z=
1119.4.
1
Absorption is reported as the n value in cmꢀ1. H NMR and
13C NMR were recorded on a Bruker AM 400 spectrometer.
Chemical shifts are reported as d values (ppm). High-resolu-
tion mass spectra (HRMS) were determined on a Finnigan
MAT90.
Detailed experimental procedures and characterization
data for compounds 2–34 are given in the Supporting Infor-
mation.
Deprotection of Dimer 31
Allyl (methyl 2-O-benzoyl-3-O-benzyl-b-d-glucopyranosyl-
uronate)-(1!3)-(4-O-acetyl-6-O-benzyl-2-deoxy-2-acetami-
Acknowledgements
do-b-d-glucopyranosyl)-(1!4)-(methyl
2-O-benzoyl-3-O-
This work was supported by a grant to JPS from the Deut-
sche Forschungsgemeinschaft under the auspices of the
Schwerpunkt Program SPP1190 (tumor-vessel interface).
benzyl-b-d-glucopyranosyluronate)-(1!3)-4-O-acetyl-6-O-
benzyl-2-deoxy-2-acetamido-b-d-glucopyranoside (35): Allyl
(methyl
2-O-benzoyl-3-O-benzyl-b-d-glucopyranosyluro-
nate)-(1!3)-(4-O-acetyl-6-O-benzyl-2-deoxy-2-trichloroace-
tamido-b-d-glucopyranosyl)-(1!4)-(methyl 2-O-benzoyl-3-
O-benzyl-b-d-glucopyranosyluronate)-(1!3)-4-O-acetyl-6-
O-benzyl-2-deoxy-2-trichloroacetamido-b-d-glucopyranoside References
(31) (0.20 g, 0.13 mmol) was dissolved in 1,4-dioxane (5 mL)
and AcOH (0.37 mL, 50 equiv.) and activated zinc powder
(0.42 g, 50 equiv.) were added. The reaction mixture was
stirred at room temperature until complete conversion
(TLC/MALDI control). In those cases where the reaction
was not completed, again the same amounts of AcOH and
activated zinc powder were added. This procedure was re-
peated several times until complete conversion. After com-
pletion, the reaction mixture was diluted with water and
neutralized with saturated sodium bicarbonate solution. The
[1] K. Meyer, J. Palmer, J. Biol. Chem. 1934, 107, 629–634.
[2] T. C. Laurent, J. R. E. Fraser, FASEB J. 1992, 6, 2397–
2404.
[3] C. B. Knudson, W. Knudson, FASEB J. 1993, 7, 1233–
1241.
[4] C. Zeng, B. P. Toole, S. D. Kinney, J-W. Kuo, I. Stamen-
kovic, Int. J. Cancer 1998, 77, 396–401.
[5] R. Stern, A. A. Asari, K. N. Sugahara, Eur. J. Cell Biol.
2006, 85, 699–715.
Adv. Synth. Catal. 2010, 352, 2657 – 2662
ꢃ 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2661